Drugs / SDX-101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00151736 | Sep 2004 → Feb 2006 | B-cell chronic lymphocytic leukemia | Cephalon | Terminated | No outcome recorded |
| Phase 2 | NCT00293111 | Feb 2002 → Oct 2003 | plasma cell myeloma | Cephalon | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SDX-101 | “Safety and Efficacy of SDX-101 (R-Etodolac) in Combination With Chlorambucil, and That of Chlorambucil Alone, in Patients With Chronic Lymphocytic Leukemia (CLL)” NCT00151736 ↗1“SDX-101 (R-Etodolac)” NCT00293111 ↗ |
| Known as | KS-1056 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1716091 ↗ |
| Known as | R-Etodolac | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00293111 ↗ |
| Known as | RAK-593 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1716091 ↗ |
| Modality | Small molecule | — CHEMBL1716091 ↗ |
| Target | RXRA | “Retinoid X receptor alpha modulator” CHEMBL1716091 ↗ |